Objectives: The genetic barrier (defined as the number of genetic transitions/transversions needed to produce a resistance mutation) can differ between HIV-1 subtypes. The genetic barrier for the new attachment inhibitor BMS-626529 was evaluated in five HIV-1 subtypes.
Introduction
In HIV treatment, attachment inhibitors (AIs) represent a novel class of entry inhibitors. The BMS-626529 (prodrug BMS-663068) AI binds to the HIV-1 envelope glycoprotein gp120, preventing viral entry into host cells by inhibiting the interaction between the virus and the cellular receptor CD4. 1 In a recent Phase II clinical trial, the BMS-663068 AI, in combination with raltegravir and tenofovir, showed favourable safety and tolerability profiles with similar efficacy in comparison with atazanavir/ritonavir up to week 24 in treatment-experienced patients. 2 Some in vitro studies showed that BMS-626529 demonstrated activity against most subtypes. 3 However, a differential antiviral activity of this drug showed the possibility of natural resistance for CRF01_AE recombinant and HIV-1 group O. 3 In vitro passage experiments evidenced substitutions in the CD4 binding site in HIV gp120 that confer resistance to BMS-626529 (L116P, A204D, M426L, M434I-V506M and M475I). 3 In an in vivo study in which BMS-626529 in its prodrug form was administered as monotherapy for 8 days to patients infected with HIV-1 B subtypes, the env substitution M426L was found to be strongly associated with low susceptibility to BMS-626529. S375T, M434I and M475I may contribute to loss of phenotypic susceptibility in some nonresponders. 4 Overall, the data suggested that susceptibility to BMS-626529 was highly variable and a clinical cut-off has not yet been determined. 4 The study of the genetic barrier helps in the understanding of genetic variations between different HIV subtypes, especially their ability to develop resistance mutations. Previous studies have evaluated the genetic barrier between different subtypes for other therapeutic classes, such as NRTIs, NNRTIs, PIs and integrase inhibitors (INIs). 5 -8 However, there are few data on the HIV envelope, which is characterized by high genetic variability. In this study, the genetic barrier, defined as the number of genetic variations needed to produce a resistance mutation to BMS-626529 AI, was evaluated for five HIV-1 subtypes: B versus non-B (C, D, CRF02_AG and CRF01_AE).
Methods
Three-hundred sequences of the env gene encoding the gp120 protein (60 for each B, C and D subtype; 60 for each CRF02_AG and CRF01_AE recombinant) from antiretroviral-naive patients were analysed. All sequences for C, D, CRF01_AE subtypes and 30 sequences for CRF02_AG were collected from the Los Alamos database. 9 Sequences for all B and 30 sequences for CRF02_AG subtypes were collected from the database of Pitié-Salpêtrière and Bichat Hospitals.
Analysis of sequences was performed using the previously published method. 8 In summary, transitions were defined by the replacement of a purine by another purine (A↔G) or of a pyrimidine by another pyrimidine (C↔T) and transversions were defined by the replacement of a purine by a pyrimidine and vice versa A↔C A↔T G↔C G↔T. 7 For the calculation of the genetic barrier, the smallest number of transitions T (scored as 1) and/or transversions V (scored as 2.5) required for evolution to BMS-626529 AI resistance-associated mutations was used.
Seven amino acid positions at which there were nine substitutions conferring resistance to BMS-626529 were explored: L116P, A204D, S375H/M/T, M426L, M434I, M475I and V506M.
Results
In order to compare the genetic barrier to BMS-626529 AI resistance between five different HIV-1 recombinants and subtypes (B, C, D, CRF02_AG and CRF01_AE), a total of 300 sequences of the env gene encoding the gp120 protein (60 sequences for each subtype) were evaluated at seven positions.
Primary resistance to BMS-626529 AI was observed in this population of 300 sequences from antiretroviral-naive patients for four positions of the env gene encoding the gp120 protein (375, 426, 434 and 475) ( Table 1 ). The S375H and S375T mutations were detected in 100% of the CRF01_AE recombinant and 9% of the D subtype sequences, respectively. For CRF02_AG recombinant and C and D subtypes, M426L was observed in 2%, 6% and 25% of sequences, respectively. The M434I substitution was present in 5%, 7% and 13% of sequences of the C, CRF01_AE and CRF02_AG subtypes, respectively. The M475I substitution was observed in 88% of the CRF01_AE recombinants. No primary resistance mutation was observed in the B subtype. Neither L116P nor A204D was observed in any subtype.
The majority (five out of seven) of amino acid positions studied were relatively conserved between the HIV-1 subtypes and recombinants, leading to a similar genetic barrier to mutations associated with resistance to BMS-626529 AI: .63% had CTA at position 116, .75% had ATG at position 426, .80% had ATG at position 434, .97% had ATG at position 475 (except the CRF01_AE sequences, of which 88% presented natural polymorphisms leading to resistance) and .77% had GTG at position 506. However, at position 116, 25% of C subtype sequences and 33% of CRF02_AG recombinant sequences showed other codons, leading to a higher genetic barrier (minimal score 2 for TTA versus 1 for CTA) ( Table 1 and Figure 1 ). At position 506, the CRF02_AG recombinant showed a higher genetic barrier in 23% of sequences (minimal score 6 for GGT versus 1 for GTG) ( Table 1 and Figure 1) .
At the two remaining positions (204 and 375), different predominant codons were observed. At position 204, two codons were predominant: GCC for the B and C subtypes and GCT for the CRF02_AG recombinant, the CRF01_AE recombinant and the D subtype. However, these two codons showed a similar minimal score of 2.5 for BMS-626529 AI resistance mutations. At position 375, two codons were also predominant (AGT for subtype B and CRF02_AG recombinant and AGC for subtypes C and D). These codons had similar minimal scores for the considered mutations (H, M and T). It should be noted that 25% of CRF02_AG recombinants had the ATT codon, leading to a lower minimal score for two mutations in comparison with the predominant codon (2.5 versus 5 for M; 1 versus 2.5 for T) ( Table 1 and Figure 1 ).
Discussion
In the development of drug resistance, the genetic barrier is an important factor that may be influenced by high genetic diversity of HIV. In this study, the genetic barrier to the new BMS-626529 AI was explored for the first time for five different subtypes and recombinants (B, C, D, CRF02_AG and CRF01_AE). The majority of the studied amino acid positions (116, 426, 434, 475 and 506) were relatively conserved between HIV-1 subtype B and other studied subtypes, leading to a similar genetic barrier to BMS-626529 AI resistance mutations. Indeed, none of the studied subtypes was more susceptible to the acquisition of resistance mutations to BMS-626529 AI. However, this genetic barrier could be slightly different for a minority of CRF02_AG and C sequences, depending on the naturally present codon (the barrier is higher or lower depending on the amino acid position).
Despite the high variability of the HIV envelope, the genetic barrier was similar for most codons between different subtypes and recombinants (B, C, D, CRF02_AG, CRF01_AE) for BMS-626529 AI resistance mutations. This result could be related to the fact that most substitutions identified previously in BMS-378806-and BMS-488043-resistant viruses mapped to the conserved regions (C1, C2, C4 and C5) of the HIV-1 envelope. 4 Several other studies showed globally a high degree of conservation for different antiretroviral classes (NRTIs, NNRTIs, PIs and INIs), leading to a similar genetic barrier for antiretroviral drug resistance substitutions. 5 -8 However, in the non-B subtypes, particularly the CRF02_AG recombinant in comparison with the B subtype, a high genetic barrier was observed at only a few positions, such as G140S, G140C and V151I in the integrase gene, which could play a role in resistance to raltegravir or elvitegravir. 6 Similarly, a higher genetic barrier for V179D and V179F in the reverse transcriptase gene was observed, suggesting that it would be more difficult to produce resistance to etravirine in the CRF02_AG recombinant than in the B subtype. 5 Furthermore, in our study, the CRF02_AG recombinant showed a higher genetic barrier at positions 116 and 506, suggesting greater difficulty for this subtype to acquire BMS-626529 AI resistance mutations at those positions. A similar result was observed with subtype C at position 116.
We confirm that previously described mutations associated with resistance to BMS-626529 AI can exist naturally in sequences from naive patients. 3,4,10 -12 This has been shown for the CRF01_AE recombinant, which harboured S375H in 100%, M434I in 7% and M475I in 88% of the sequences and to a lesser extent for the C subtype (M426L 6%, M434I 5%), D subtype (S375T 9%, M426L 25%) and CRF02_AG recombinant (M426L 2%, M434I 13%). Class resistance in CRF01_AE recombinant viruses was previously mapped to the 375H and 475I substitutions, found in the vast majority of the viruses.
4 M426L appeared at a frequency of 3.3% in CRF02_AG recombinants studied in a previous analysis and the overall frequency of the M434I substitution is 8% of all isolates in the LANL database and 15.4% of CRF02_AG recombinants. 4 In vitro, BMS-626529 displayed activity against almost all subtypes tested, with the B subtype appearing to be most susceptible, followed by subtype C. Only the CRF01_AE recombinant was not susceptible to BMS-626529 in vitro, which can probably be explained by the presence of natural polymorphism. 3 In summary, a similar genetic barrier at positions associated with BMS-626529 AI resistance in different subtypes and recombinants was observed despite the known great variability of the HIV envelope. However, a minority of CRF02_AG and C sequences had a higher genetic barrier, suggesting that it would be more difficult for these recombinants and subtypes to acquire mutations at those positions. The development of resistance to BMS-626529 in clinical trials should be carefully studied, taking into account the subtype.
